Cardiol Therapeutics (CRDL) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 11.3% versus a loss of 63.4%. Over five years, VYGR leads with a -50.0% price change compared with -60.1% for CRDL. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $95.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | VYGR |
|---|---|---|
| Share price | $0.8626 | $1.53 |
| Market cap | $110.14M | $95.21M |
| 1-day change | -2.28% | -4.97% |
| YTD return | -9.58% | -61.07% |
| 1-year return | -11.35% | -63.40% |
| 5-year return | -60.06% | -50.00% |
| EPS (TTM) | $-0.24 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $40.37M |
| Revenue growth (YoY) | — | -49.53% |
| Net income (latest FY) | — | $-119.72M |
| Operating margin | — | -326.56% |
| Net margin | — | -296.53% |
| 52-week high | $2.34 | $5.48 |
| 52-week low | $0.8417 | $1.48 |
| Distance from 52-week high | -63.14% | -72.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +874.96% | +829.41% |
| Average volume | 1.20M | 770.24K |
| Shares outstanding | 127.69M | 62.23M |
| Employees | 18 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed VYGR by 52.1 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
CRDL vs VYGR FAQ
Which is bigger, Cardiol Therapeutics or Voyager Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $95.21M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, CRDL or VYGR?
CRDL returned -11.35% over the past 12 months, compared with -63.40% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.